Rate My Professor Gregg Semenza

Semenza's laboratory has produced over 400 peer-reviewed publications, cited more than 150,000 times, including landmark papers such as 'A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation' (Molecular and Cellular Biology, 1992), 'Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension' (Proceedings of the National Academy of Sciences USA, 1995), 'Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1' (Molecular and Cellular Biology, 1996), and 'Targeting HIF-1 for cancer therapy' (Nature Reviews Cancer, 2003). These findings have transformed understanding of hypoxia responses in cancer progression, myocardial and cerebral ischemia, chronic lung disease, and ocular neovascularization disorders. Semenza's profound impact on biomedical science is evidenced by major awards, including the 2019 Nobel Prize in Physiology or Medicine for discoveries on how cells sense and adapt to oxygen availability, the 2016 Albert Lasker Award for Basic Medical Research, the 2018 Massry Prize, the 2014 Wiley Prize in Biomedical Sciences, and election to the National Academy of Sciences and National Academy of Medicine. He also serves as Deputy Editor of the Journal of Clinical Investigation.